ANDREW RAYMOND RUSINKO
Pilots at Mandy Way, Arlington, TX
License number
Texas A4878333
Issued Date
Aug 2016
Expiration Date
Aug 2017
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
2502 Mandy Way, Arlington, TX 76017
Professional information
Andrew Rusinko - Arlington, TX
Work:
NOVARTIS (NIBR) / Alcon - Fort Worth, TX
Associate Technical Director Alcon - Fort Worth, TX
Assistant Technical Director GLAXO SMITH KLINE - Research Triangle Park, NC
Project Manager - Research Information Resources
Associate Technical Director Alcon - Fort Worth, TX
Assistant Technical Director GLAXO SMITH KLINE - Research Triangle Park, NC
Project Manager - Research Information Resources
Education:
THE UNIVERSITY OF TEXAS AT AUSTIN - Austin, TX
Ph.D. in Pharmaceutics TRINITY UNIVERSITY - San Antonio, TX
M.S. in Chemistry WESTERN MARYLAND COLLEGE (now McDaniel College) - Westminster, MD
B.A. in Chemistry
Ph.D. in Pharmaceutics TRINITY UNIVERSITY - San Antonio, TX
M.S. in Chemistry WESTERN MARYLAND COLLEGE (now McDaniel College) - Westminster, MD
B.A. in Chemistry
Skills:
KNIME, Spotfire, Data-mining R, Splus, SAS,PERL, Python C / C++ / Visual Basic ORACLE
(Indazol-5-Yl)-Pyrazines And (1,3-Dihydro-Indol-2-One)-Pyrazines For Treating Glaucoma And Controlling Intraocular Pressure
US Patent:
7655662, Feb 2, 2010
Filed:
Dec 19, 2006
Appl. No.:
11/612894
Inventors:
Mark R. Hellberg - Arlington TX, US
Najam A. Sharif - Keller TX, US
Jesse A. May - Fort Worth TX, US
Andrew Rusinko - Arlington TX, US
Hwang-Hsing Chen - Arlington TX, US
Najam A. Sharif - Keller TX, US
Jesse A. May - Fort Worth TX, US
Andrew Rusinko - Arlington TX, US
Hwang-Hsing Chen - Arlington TX, US
Assignee:
Alcon Research, Ltd. - Fort Worth TX
International Classification:
A61K 31/496, A61K 31/55, A61K 31/50, A61K 31/52, A61K 31/19
US Classification:
51425505, 514218, 514248, 514249, 51426322, 514573
Abstract:
Methods for using (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines, are disclosed herein.
6-Aminoimidazo[1,2-B]Pyridazine Analogs As Rho Kinase Inhibitors For The Treatment Of Rho Kinase-Mediated Diseases And Conditions
US Patent:
7820670, Oct 26, 2010
Filed:
Dec 19, 2007
Appl. No.:
11/960476
Inventors:
Hwang-Hsing Chen - Fort Worth TX, US
Andrew Rusinko - Arlington TX, US
Mark R. Hellberg - Arlington TX, US
Bryon S. Severns - Arlington TX, US
Alan J. Henderson - Albany NY, US
Cheng Guo - Schenectady NY, US
Mark Hadden - Albany NY, US
Andrew Rusinko - Arlington TX, US
Mark R. Hellberg - Arlington TX, US
Bryon S. Severns - Arlington TX, US
Alan J. Henderson - Albany NY, US
Cheng Guo - Schenectady NY, US
Mark Hadden - Albany NY, US
Assignee:
Alcon Research, Ltd. - Fort Worth TX
International Classification:
A61K 31/501
US Classification:
51425206
Abstract:
Methods for using 6-aminoimidazo[1,2-b]pyridazine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of 6-aminoimidazo[1,2-b]pyridazine analogs, are disclosed herein.
Aminopyrazine Analogs For Treating Glaucoma And Other Rho Kinase-Mediated Diseases And Conditions
US Patent:
2010021, Aug 26, 2010
Filed:
May 5, 2010
Appl. No.:
12/774399
Inventors:
Mark R. Hellberg - Arlington TX, US
Andrew Rusinko - Arlington TX, US
Alan J. Henderson - Albany NY, US
Cheng Guo - Schenectady NY, US
Mark Hadden - Albany NY, US
Hélène Y. Decornez - Clifton Park NY, US
Andrew Rusinko - Arlington TX, US
Alan J. Henderson - Albany NY, US
Cheng Guo - Schenectady NY, US
Mark Hadden - Albany NY, US
Hélène Y. Decornez - Clifton Park NY, US
Assignee:
ALCON, INC. - Hunenberg
International Classification:
A61K 31/551, A61K 31/55, A61K 31/497, C07D 401/14, C07D 401/04, A61P 27/06, C07D 403/14, C07D 471/04, A61P 27/02
US Classification:
51421705, 514218, 51425211, 51425505, 540575, 544357, 544405
Abstract:
Methods for using aminopyrazine analogs to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of aminopyrazine analogs, are also disclosed.
3,6-Substituted Imidazol[1,2-B]Pyridazine Analogs For Treating Allergic And Inflammatory Diseases
US Patent:
7713975, May 11, 2010
Filed:
Jan 12, 2006
Appl. No.:
11/330590
Inventors:
Mark R. Hellberg - Arlington TX, US
Steven T. Miller - Arlington TX, US
Andrew Rusinko - Arlington TX, US
Steven T. Miller - Arlington TX, US
Andrew Rusinko - Arlington TX, US
Assignee:
Alcon, Inc. - Hunenberg
International Classification:
A61K 31/50, A61K 31/501, C07D 237/26, C07D 487/00, C07D 235/00, C07D 233/00
US Classification:
51425201, 51425205, 544233, 544234, 544236, 5483017, 5483021, 5483111
Abstract:
Methods for treating an allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition characterized by administering a composition which contains a therapeutically effective amount of a 3,6-substituted imidazol[1,2-b]pyridazine compound.
5-Substituted 2-Aminopyridine Analogs For Treating Allergic And Inflammatory Diseases
US Patent:
7799778, Sep 21, 2010
Filed:
Jan 12, 2006
Appl. No.:
11/330629
Inventors:
Mark R. Hellberg - Arlington TX, US
Steven T. Miller - Arlington TX, US
Andrew Rusinko - Arlington TX, US
Steven T. Miller - Arlington TX, US
Andrew Rusinko - Arlington TX, US
Assignee:
Alcon, Inc. - Hunenberg
International Classification:
A61K 31/535, A61K 31/50, A61K 31/497, A61K 31/44, A01N 43/58, A01N 43/42, C07D 221/18, C07D 221/22, C07D 401/00, C07D 421/00, C07D 405/00
US Classification:
5142295, 5142315, 5142355, 5142378, 514249, 51425213, 51425301, 51425302, 514279, 546 26, 5462681, 5462821
Abstract:
Methods for treating an allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition characterized by administering a composition which contains a therapeutically effective amount of a 5-substituted 2-aminopyridine compound.
3,6-Substituted Imidazol[1,2-B]Pyridazine Analogs For Treating Allergic And Inflammatory Diseases
US Patent:
7906512, Mar 15, 2011
Filed:
Mar 10, 2010
Appl. No.:
12/720808
Inventors:
Mark R. Hellberg - Arlington TX, US
Steven T. Miller - Arlington TX, US
Andrew Rusinko - Arlington TX, US
Steven T. Miller - Arlington TX, US
Andrew Rusinko - Arlington TX, US
Assignee:
Alcon, Inc. - Hunenberg
International Classification:
A01N 43/58, A01N 43/60, A01N 43/52, A61K 31/50, A61K 31/495, A61K 31/501, A61K 31/415, C07D 487/00, C07D 401/00, C07D 403/00, C07D 405/00, C07D 409/00, C07D 235/02, C07D 403/02
US Classification:
514248, 51425206, 514393, 544236, 544238, 5483031
Abstract:
Methods for treating an allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition characterized by administering a composition which contains a therapeutically effective amount of a 3,6-substituted imidazol[1,2-b]pyridazine compound.
Use Of Mdck Cell Line To Predict Corneal Penetration Of Drugs
US Patent:
2005023, Oct 27, 2005
Filed:
Apr 25, 2005
Appl. No.:
11/114649
Inventors:
Andrew Rusinko - Arlington TX, US
Mark Hellberg - Arlington TX, US
Jesse May - Fort Worth TX, US
Geoffrey Owen - Southlake TX, US
Mark Hellberg - Arlington TX, US
Jesse May - Fort Worth TX, US
Geoffrey Owen - Southlake TX, US
International Classification:
C12Q001/00, G06F019/00, G01N033/48, G01N033/50
US Classification:
435004000, 702019000
Abstract:
A new method of evaluating the ability of drug molecules to penetrate the cornea is described. The permeation rate of the drug molecules in MDCK cells is utilized to predict the ability of the molecules to penetrate the cornea. The method is useful for in vitro screening of potential new ophthalmic drugs, as well as in the design of new drug molecules for topical ocular administration.
Aminopyrazine Analogs For Treating Glaucoma And Other Rho Kinase-Mediated Diseases And Conditions
US Patent:
2006014, Jun 29, 2006
Filed:
Dec 14, 2005
Appl. No.:
11/302825
Inventors:
Mark Hellberg - Arlington TX, US
Andrew Rusinko - Arlington TX, US
Andrew Rusinko - Arlington TX, US
International Classification:
A61K 31/497, C07D 403/02, A61K 31/4965
US Classification:
514255050, 544405000
Abstract:
Methods for using aminopyrazine analogs to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of aminopyrazine analogs, are also disclosed.
Use Of Mdck Cell Line To Predict Corneal Penetration Of Drugs
US Patent:
2008013, Jun 12, 2008
Filed:
Oct 12, 2007
Appl. No.:
11/871426
Inventors:
Andrew RUSINKO - Arlington TX, US
Mark R. HELLBERG - Arlington TX, US
Jesse Albert May - Fort Worth TX, US
Geoffrey Robert Owen - Southlake TX, US
Mark R. HELLBERG - Arlington TX, US
Jesse Albert May - Fort Worth TX, US
Geoffrey Robert Owen - Southlake TX, US
Assignee:
ALCON, INC. - Hunenberg
International Classification:
C12Q 1/02, A61K 47/00, A61P 27/02
US Classification:
435 29, 514789
Abstract:
A new method of evaluating the ability of drug molecules to penetrate the cornea is described. The permeation rate of the drug molecules in MDCK cells is utilized to predict the ability of the molecules to penetrate the cornea. The method is useful for in vitro screening of potential new ophthalmic drugs, as well as in the design of new drug molecules for topical ocular administration.